Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook

Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital

April 30, 2024 4:50 PM EDT

BMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.

The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More

Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald

April 30, 2024 2:01 PM EDT

Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.

The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More

Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion

April 30, 2024 6:50 AM EDT

By Bhanvi Satija and Patrick Wingrove

(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%.

Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro, for which most doses are in shortage due to high demand.

Skyrocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the Indianapolis-based drugmaker's market value above $700 billion - surpassing that of Tesla and Walmart.

... More

Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance

April 30, 2024 6:48 AM EDT

Eli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $2.58, $0.10 better than the analyst estimate of $2.48. Revenue for the quarter came in at $8.77 billion versus the consensus estimate of $8.94 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2024 EPS of $13.50-$14.00, versus the... More